ID APCL_HUMAN Reviewed; 2303 AA. AC O95996; Q05BW4; Q9UBZ1; Q9UEM8; Q9UQJ8; Q9UQJ9; Q9Y632; DT 15-JAN-2008, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-1999, sequence version 1. DT 12-AUG-2020, entry version 159. DE RecName: Full=Adenomatous polyposis coli protein 2 {ECO:0000305}; DE AltName: Full=Adenomatous polyposis coli protein-like; DE Short=APC-like; GN Name=APC2 {ECO:0000312|HGNC:HGNC:24036}; Synonyms=APCL; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, INTERACTION WITH CTNNB1, RP AND TISSUE SPECIFICITY. RC TISSUE=Brain; RX PubMed=9823329; RA Nakagawa H., Murata Y., Koyama K., Fujiyama A., Miyoshi Y., Monden M., RA Akiyama T., Nakamura Y.; RT "Identification of a brain-specific APC homologue, APCL, and its RT interaction with beta-catenin."; RL Cancer Res. 58:5176-5181(1998). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1). RX PubMed=10551328; DOI=10.1111/j.1349-7006.1999.tb00845.x; RA Nakagawa H., Koyama K., Monden M., Nakamura Y.; RT "Analysis of APCL, a brain-specific adenomatous polyposis coli homologue, RT for mutations and expression in brain tumors."; RL Jpn. J. Cancer Res. 90:982-986(1999). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-1521 (ISOFORM 2), AND NUCLEOTIDE SEQUENCE RP [GENOMIC DNA] OF 34-86 AND 476-555 (ISOFORM 2). RA Carr I.M., Markham A.F., Colleta P.L., Wai L., Askham J., Morrison E., RA Meredith D.M.; RT "APC2 alternatively spliced cDNA sequence."; RL Submitted (NOV-1998) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-731 (ISOFORM 3), NUCLEOTIDE SEQUENCE RP [GENOMIC DNA] OF 618-2303 (ISOFORM 3), FUNCTION, INTERACTION WITH AXIN2, RP TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE. RC TISSUE=Kidney; RX PubMed=10021369; DOI=10.1016/s0960-9822(99)80024-4; RA van Es J.H., Kirkpatrick C., van de Wetering M., Molenaar M., Miles A., RA Kuipers J., Destree O., Peifer M., Clevers H.; RT "Identification of APC2, a homologue of the adenomatous polyposis coli RT tumour suppressor."; RL Curr. Biol. 9:105-108(1999). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-702 (ISOFORM 1). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP INTERACTION WITH TP53BP2, AND SUBCELLULAR LOCATION. RX PubMed=10646860; RA Nakagawa H., Koyama K., Murata Y., Morito M., Akiyama T., Nakamura Y.; RT "APCL, a central nervous system-specific homologue of adenomatous polyposis RT coli tumor suppressor, binds to p53-binding protein 2 and translocates it RT to the perinucleus."; RL Cancer Res. 60:101-105(2000). RN [8] RP INTERACTION WITH MAPRE1 AND MAPRE3, AND SUBCELLULAR LOCATION. RC TISSUE=Fetal brain; RX PubMed=10644998; DOI=10.1038/sj.onc.1203308; RA Nakagawa H., Koyama K., Murata Y., Morito M., Akiyama T., Nakamura Y.; RT "EB3, a novel member of the EB1 family preferentially expressed in the RT central nervous system, binds to a CNS-specific APC homologue."; RL Oncogene 19:210-216(2000). RN [9] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH APC, AND TISSUE RP SPECIFICITY. RX PubMed=11691822; RA Jarrett C.R., Blancato J., Cao T., Bressette D.S., Cepeda M., Young P.E., RA King C.R., Byers S.W.; RT "Human APC2 localization and allelic imbalance."; RL Cancer Res. 61:7978-7984(2001). RN [10] RP INVOLVEMENT IN SOTOS3, FUNCTION, SUBCELLULAR LOCATION, AND REGION. RX PubMed=25753423; DOI=10.1016/j.celrep.2015.02.011; RA Almuriekhi M., Shintani T., Fahiminiya S., Fujikawa A., Kuboyama K., RA Takeuchi Y., Nawaz Z., Nadaf J., Kamel H., Kitam A.K., Samiha Z., RA Mahmoud L., Ben-Omran T., Majewski J., Noda M.; RT "Loss-of-function mutation in APC2 causes Sotos syndrome features."; RL Cell Rep. 10:1585-1598(2015). RN [11] RP VARIANTS [LARGE SCALE ANALYSIS] SER-562 AND SER-2003. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [12] {ECO:0000305} RP VARIANT ASN-1921. RX PubMed=29120066; DOI=10.1111/cge.13171; RA Mejecase C., Mohand-Said S., El Shamieh S., Antonio A., Condroyer C., RA Blanchard S., Letexier M., Saraiva J.P., Sahel J.A., Audo I., Zeitz C.; RT "A novel nonsense variant in REEP6 is involved in a sporadic rod-cone RT dystrophy case."; RL Clin. Genet. 93:707-711(2018). RN [13] RP INVOLVEMENT IN CDCBM10, AND VARIANTS CDCBM10 246-SER--GLU-2303 DEL; RP 361-GLN--GLU-2303 DEL AND 628-GLN--GLU-2303 DEL. RX PubMed=31585108; DOI=10.1016/j.ajhg.2019.08.013; RA Lee S., Chen D.Y., Zaki M.S., Maroofian R., Houlden H., Di Donato N., RA Abdin D., Morsy H., Mirzaa G.M., Dobyns W.B., McEvoy-Venneri J., RA Stanley V., James K.N., Mancini G.M.S., Schot R., Kalayci T., Altunoglu U., RA Karimiani E.G., Brick L., Kozenko M., Jamshidi Y., Manzini M.C., RA Beiraghi Toosi M., Gleeson J.G.; RT "Bi-allelic Loss of Human APC2, Encoding Adenomatous Polyposis Coli Protein RT 2, Leads to Lissencephaly, Subcortical Heterotopia, and Global RT Developmental Delay."; RL Am. J. Hum. Genet. 105:844-853(2019). CC -!- FUNCTION: Stabilizes microtubules and may regulate actin fiber dynamics CC through the activation of Rho family GTPases (PubMed:25753423). May CC also function in Wnt signaling by promoting the rapid degradation of CC CTNNB1 (PubMed:10021369, PubMed:11691822, PubMed:9823329). CC {ECO:0000269|PubMed:10021369, ECO:0000269|PubMed:11691822, CC ECO:0000269|PubMed:25753423, ECO:0000269|PubMed:9823329}. CC -!- SUBUNIT: Interacts with PSRC1 (By similarity). Interacts with APC, CC CTNNB1, MAPRE1, MAPRE3, TP53BP2 and possibly with AXIN2. {ECO:0000250, CC ECO:0000269|PubMed:10021369, ECO:0000269|PubMed:10644998, CC ECO:0000269|PubMed:10646860, ECO:0000269|PubMed:11691822, CC ECO:0000269|PubMed:9823329}. CC -!- INTERACTION: CC O95996; Q15691: MAPRE1; NbExp=3; IntAct=EBI-1053045, EBI-1004115; CC O95996; Q9UPY8: MAPRE3; NbExp=7; IntAct=EBI-1053045, EBI-726739; CC O95996; Q13625: TP53BP2; NbExp=4; IntAct=EBI-1053045, EBI-77642; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton CC {ECO:0000269|PubMed:10644998, ECO:0000269|PubMed:11691822, CC ECO:0000269|PubMed:25753423}. Golgi apparatus CC {ECO:0000269|PubMed:11691822}. Cytoplasm {ECO:0000269|PubMed:11691822}. CC Cytoplasm, perinuclear region {ECO:0000269|PubMed:10646860}. CC Note=Associated with actin filaments (PubMed:11691822, CC PubMed:25753423). Associated with microtubule network (PubMed:10644998, CC PubMed:11691822, PubMed:25753423). {ECO:0000269|PubMed:10644998, CC ECO:0000269|PubMed:11691822, ECO:0000269|PubMed:25753423}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=O95996-1; Sequence=Displayed; CC Name=2; CC IsoId=O95996-2; Sequence=VSP_030106; CC Name=3; CC IsoId=O95996-3; Sequence=VSP_030107; CC -!- TISSUE SPECIFICITY: Widely expressed (at protein level). Specifically CC expressed in the CNS. {ECO:0000269|PubMed:10021369, CC ECO:0000269|PubMed:11691822, ECO:0000269|PubMed:9823329}. CC -!- DEVELOPMENTAL STAGE: Expressed in fetal brain. CC {ECO:0000269|PubMed:10021369}. CC -!- DISEASE: Sotos syndrome 3 (SOTOS3) [MIM:617169]: A form of Sotos CC syndrome, a childhood overgrowth syndrome characterized by prenatal and CC postnatal overgrowth, developmental delay, mental retardation, advanced CC bone age, and abnormal craniofacial morphology. SOTOS3 patients do not CC have advanced bone age, hypotonia, seizures, or autism. SOTOS3 CC transmission pattern is consistent with autosomal recessive CC inheritance. {ECO:0000269|PubMed:25753423}. Note=The disease is caused CC by mutations affecting the gene represented in this entry. CC -!- DISEASE: Cortical dysplasia, complex, with other brain malformations 10 CC (CDCBM10) [MIM:618677]: An autosomal recessive disorder of aberrant CC neuronal migration during brain development. CDCBM10 is clinically CC characterized by onset in infancy of global developmental delay, CC impaired intellectual development, seizures, inability to ambulate, and CC absent language. Brain imaging shows lissencephaly, cortical dysplasia, CC subcortical heterotopia, and paucity of white matter. CC {ECO:0000269|PubMed:31585108}. Note=The disease is caused by mutations CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the adenomatous polyposis coli (APC) family. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAD28183.1; Type=Frameshift; Evidence={ECO:0000305}; CC Sequence=AAF01784.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence.; Evidence={ECO:0000305}; CC Sequence=CAA10317.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAB61207.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB012162; BAA34611.1; -; mRNA. DR EMBL; AB022529; BAA75469.1; -; Genomic_DNA. DR EMBL; CH471139; EAW69498.1; -; Genomic_DNA. DR EMBL; AF110334; AAD28183.1; ALT_FRAME; mRNA. DR EMBL; AF110335; AAD29273.1; -; Genomic_DNA. DR EMBL; AF110337; AAD29274.1; -; Genomic_DNA. DR EMBL; AF110336; AAD29274.1; JOINED; Genomic_DNA. DR EMBL; AF128222; AAF01784.1; ALT_SEQ; mRNA. DR EMBL; AJ012652; CAB61207.1; ALT_SEQ; mRNA. DR EMBL; AJ131187; CAA10317.1; ALT_INIT; Genomic_DNA. DR EMBL; BC032573; AAH32573.1; -; mRNA. DR CCDS; CCDS12068.1; -. [O95996-1] DR RefSeq; NP_005874.1; NM_005883.2. [O95996-1] DR RefSeq; XP_006722672.1; XM_006722609.3. [O95996-1] DR SMR; O95996; -. DR BioGRID; 115585; 7. DR ComplexPortal; CPX-440; Beta-catenin destruction core complex, variant 4. DR ComplexPortal; CPX-442; Beta-catenin destruction core complex, variant 6. DR ComplexPortal; CPX-443; Beta-catenin destruction core complex, variant 8. DR ComplexPortal; CPX-99; Beta-catenin destruction core complex, variant 2. DR ELM; O95996; -. DR IntAct; O95996; 6. DR MINT; O95996; -. DR STRING; 9606.ENSP00000442954; -. DR CarbonylDB; O95996; -. DR iPTMnet; O95996; -. DR PhosphoSitePlus; O95996; -. DR BioMuta; APC2; -. DR jPOST; O95996; -. DR MassIVE; O95996; -. DR PaxDb; O95996; -. DR PeptideAtlas; O95996; -. DR PRIDE; O95996; -. DR ProteomicsDB; 51171; -. [O95996-1] DR ProteomicsDB; 51172; -. [O95996-2] DR ProteomicsDB; 51173; -. [O95996-3] DR Antibodypedia; 10529; 119 antibodies. DR Ensembl; ENST00000233607; ENSP00000233607; ENSG00000115266. [O95996-1] DR Ensembl; ENST00000535453; ENSP00000442954; ENSG00000115266. [O95996-1] DR GeneID; 10297; -. DR KEGG; hsa:10297; -. DR UCSC; uc002lsr.1; human. [O95996-1] DR CTD; 10297; -. DR DisGeNET; 10297; -. DR EuPathDB; HostDB:ENSG00000115266.11; -. DR GeneCards; APC2; -. DR HGNC; HGNC:24036; APC2. DR HPA; ENSG00000115266; Tissue enriched (brain). DR MalaCards; APC2; -. DR MIM; 612034; gene. DR MIM; 617169; phenotype. DR MIM; 618677; phenotype. DR neXtProt; NX_O95996; -. DR OpenTargets; ENSG00000115266; -. DR Orphanet; 821; Sotos syndrome. DR PharmGKB; PA134906843; -. DR eggNOG; KOG2122; Eukaryota. DR GeneTree; ENSGT00530000063749; -. DR HOGENOM; CLU_001012_0_0_1; -. DR InParanoid; O95996; -. DR KO; K02085; -. DR OMA; MCAIMKL; -. DR OrthoDB; 31524at2759; -. DR PhylomeDB; O95996; -. DR TreeFam; TF106496; -. DR PathwayCommons; O95996; -. DR SignaLink; O95996; -. DR SIGNOR; O95996; -. DR BioGRID-ORCS; 10297; 8 hits in 870 CRISPR screens. DR ChiTaRS; APC2; human. DR GenomeRNAi; 10297; -. DR Pharos; O95996; Tbio. DR PRO; PR:O95996; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; O95996; protein. DR Bgee; ENSG00000115266; Expressed in paraflocculus and 193 other tissues. DR ExpressionAtlas; O95996; baseline and differential. DR Genevisible; O95996; HS. DR GO; GO:0005884; C:actin filament; IDA:BHF-UCL. DR GO; GO:0030877; C:beta-catenin destruction complex; IBA:GO_Central. DR GO; GO:0016342; C:catenin complex; IDA:MGI. DR GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005794; C:Golgi apparatus; IDA:BHF-UCL. DR GO; GO:0045171; C:intercellular bridge; IDA:HPA. DR GO; GO:0031258; C:lamellipodium membrane; IDA:BHF-UCL. DR GO; GO:0005874; C:microtubule; IEA:UniProtKB-KW. DR GO; GO:0015630; C:microtubule cytoskeleton; IDA:BHF-UCL. DR GO; GO:0030496; C:midbody; IDA:HPA. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL. DR GO; GO:0098794; C:postsynapse; IEA:Ensembl. DR GO; GO:0008013; F:beta-catenin binding; IDA:MGI. DR GO; GO:0045295; F:gamma-catenin binding; IBA:GO_Central. DR GO; GO:0008017; F:microtubule binding; IEA:InterPro. DR GO; GO:0090630; P:activation of GTPase activity; IMP:UniProtKB. DR GO; GO:0001708; P:cell fate specification; IBA:GO_Central. DR GO; GO:0016477; P:cell migration; IBA:GO_Central. DR GO; GO:0000226; P:microtubule cytoskeleton organization; IMP:UniProtKB. DR GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IDA:BHF-UCL. DR GO; GO:0007026; P:negative regulation of microtubule depolymerization; IBA:GO_Central. DR GO; GO:0007389; P:pattern specification process; IBA:GO_Central. DR GO; GO:0045732; P:positive regulation of protein catabolic process; IBA:GO_Central. DR GO; GO:0045595; P:regulation of cell differentiation; IBA:GO_Central. DR GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW. DR Gene3D; 1.25.10.10; -; 1. DR InterPro; IPR026837; APC2. DR InterPro; IPR009234; APC_basic_dom. DR InterPro; IPR026831; APC_dom. DR InterPro; IPR026818; Apc_fam. DR InterPro; IPR032038; APC_N. DR InterPro; IPR036149; APC_N_sf. DR InterPro; IPR041257; APC_rep. DR InterPro; IPR009223; APC_rpt. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR000225; Armadillo. DR InterPro; IPR009224; SAMP. DR PANTHER; PTHR12607; PTHR12607; 1. DR PANTHER; PTHR12607:SF3; PTHR12607:SF3; 1. DR Pfam; PF05956; APC_basic; 1. DR Pfam; PF16689; APC_N_CC; 1. DR Pfam; PF05923; APC_r; 4. DR Pfam; PF18797; APC_rep; 1. DR Pfam; PF00514; Arm; 1. DR Pfam; PF05924; SAMP; 2. DR SMART; SM00185; ARM; 6. DR SUPFAM; SSF48371; SSF48371; 1. DR SUPFAM; SSF58050; SSF58050; 1. DR SUPFAM; SSF82931; SSF82931; 1. PE 1: Evidence at protein level; KW Alternative splicing; Coiled coil; Cytoplasm; Cytoskeleton; KW Disease mutation; Golgi apparatus; Lissencephaly; Microtubule; KW Phosphoprotein; Polymorphism; Reference proteome; Repeat; KW Wnt signaling pathway. FT CHAIN 1..2303 FT /note="Adenomatous polyposis coli protein 2" FT /id="PRO_0000313686" FT REPEAT 302..341 FT /note="ARM 1" FT REPEAT 479..518 FT /note="ARM 2" FT REPEAT 522..562 FT /note="ARM 3" FT REPEAT 566..609 FT /note="ARM 4" FT REPEAT 615..654 FT /note="ARM 5" FT REPEAT 657..696 FT /note="ARM 6" FT REPEAT 1058..1077 FT /note="1" FT REPEAT 1150..1169 FT /note="2" FT REPEAT 1263..1282 FT /note="3" FT REPEAT 1391..1410 FT /note="4" FT REPEAT 1568..1587 FT /note="5" FT REGION 1058..1587 FT /note="5 X 20 AA approximate repeat of F-X-V-E-X-T-P-X-C-F- FT S-R-X-S-S-L-S-S-L-S" FT REGION 1058..1587 FT /note="Interaction with CTNNB1" FT /evidence="ECO:0000269|PubMed:9823329" FT REGION 1821..1900 FT /note="Required for localization to microtubules and FT function in microtubule stabilization" FT /evidence="ECO:0000269|PubMed:25753423" FT REGION 2067..2144 FT /note="Interaction with MAPRE1 and MAPRE3" FT /evidence="ECO:0000269|PubMed:10644998" FT COILED 8..59 FT /evidence="ECO:0000255" FT COILED 840..864 FT /evidence="ECO:0000255" FT COMPBIAS 1145..1196 FT /note="Ser-rich" FT COMPBIAS 1518..1622 FT /note="Pro-rich" FT COMPBIAS 1765..1953 FT /note="Pro-rich" FT MOD_RES 1585 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9Z1K7" FT MOD_RES 1587 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q9Z1K7" FT VAR_SEQ 168..441 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|Ref.4" FT /id="VSP_030106" FT VAR_SEQ 175 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:10021369" FT /id="VSP_030107" FT VARIANT 246..2303 FT /note="Missing (in CDCBM10)" FT /evidence="ECO:0000269|PubMed:31585108" FT /id="VAR_083414" FT VARIANT 361..2303 FT /note="Missing (in CDCBM10)" FT /evidence="ECO:0000269|PubMed:31585108" FT /id="VAR_083415" FT VARIANT 562 FT /note="A -> S (in a breast cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_037703" FT VARIANT 628..2303 FT /note="Missing (in CDCBM10)" FT /evidence="ECO:0000269|PubMed:31585108" FT /id="VAR_083416" FT VARIANT 1921 FT /note="H -> N" FT /evidence="ECO:0000269|PubMed:29120066" FT /id="VAR_081224" FT VARIANT 2003 FT /note="G -> S (in a breast cancer sample; somatic mutation; FT dbSNP:rs1288757495)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_037704" FT VARIANT 2241 FT /note="S -> A (in dbSNP:rs265277)" FT /id="VAR_037705" FT CONFLICT 463 FT /note="Missing (in Ref. 4; AAD28183)" FT /evidence="ECO:0000305" FT CONFLICT 526..527 FT /note="KV -> NL (in Ref. 4; AAD28183/AAD29274)" FT /evidence="ECO:0000305" FT CONFLICT 566 FT /note="E -> A (in Ref. 5; AAF01784/CAB61207)" FT /evidence="ECO:0000305" FT CONFLICT 816 FT /note="L -> Q (in Ref. 4; AAD28183)" FT /evidence="ECO:0000305" FT CONFLICT 971 FT /note="L -> P (in Ref. 4; AAD28183)" FT /evidence="ECO:0000305" FT CONFLICT 1106 FT /note="S -> I (in Ref. 4; AAD28183)" FT /evidence="ECO:0000305" FT CONFLICT 1140 FT /note="E -> G (in Ref. 5; CAA10317)" FT /evidence="ECO:0000305" FT CONFLICT 1188 FT /note="Q -> H (in Ref. 4; AAD28183)" FT /evidence="ECO:0000305" FT CONFLICT 1361 FT /note="A -> G (in Ref. 4; AAD28183)" FT /evidence="ECO:0000305" FT CONFLICT 1456 FT /note="R -> P (in Ref. 4; AAD28183)" FT /evidence="ECO:0000305" FT CONFLICT 1515 FT /note="D -> V (in Ref. 4; AAD28183)" FT /evidence="ECO:0000305" FT CONFLICT 2219 FT /note="A -> V (in Ref. 5; CAA10317)" FT /evidence="ECO:0000305" SQ SEQUENCE 2303 AA; 243949 MW; 7BF940183ACD643D CRC64; MASSVAPYEQ LVRQVEALKA ENSHLRQELR DNSSHLSKLE TETSGMKEVL KHLQGKLEQE ARVLVSSGQT EVLEQLKALQ MDITSLYNLK FQPPTLGPEP AARTPEGSPV HGSGPSKDSF GELSRATIRL LEELDRERCF LLNEIEKEEK EKLWYYSQLQ GLSKRLDELP HVETQFSMQM DLIRQQLEFE AQHIRSLMEE RFGTSDEMVQ RAQIRASRLE QIDKELLEAQ DRVQQTEPQA LLAVKSVPVD EDPETEVPTH PEDGTPQPGN SKVEVVFWLL SMLATRDQED TARTLLAMSS SPESCVAMRR SGCLPLLLQI LHGTEAAAGG RAGAPGAPGA KDARMRANAA LHNIVFSQPD QGLARKEMRV LHVLEQIRAY CETCWDWLQA RDGGPEGGGA GSAPIPIEPQ ICQATCAVMK LSFDEEYRRA MNELGGLQAV AELLQVDYEM HKMTRDPLNL ALRRYAGMTL TNLTFGDVAN KATLCARRGC MEAIVAQLAS DSEELHQVVS SILRNLSWRA DINSKKVLRE AGSVTALVQC VLRATKESTL KSVLSALWNL SAHSTENKAA ICQVDGALGF LVSTLTYKCQ SNSLAIIESG GGILRNVSSL VATREDYRQV LRDHNCLQTL LQHLTSHSLT IVSNACGTLW NLSARSARDQ ELLWDLGAVG MLRNLVHSKH KMIAMGSAAA LRNLLAHRPA KHQAAATAVS PGSCVPSLYV RKQRALEAEL DARHLAQALE HLEKQGPPAA EAATKKPLPP LRHLDGLAQD YASDSGCFDD DDAPSSLAAA AATGEPASPA ALSLFLGSPF LQGQALARTP PTRRGGKEAE KDTSGEAAVA AKAKAKLALA VARIDQLVED ISALHTSSDD SFSLSSGDPG QEAPREGRAQ SCSPCRGPEG GRREAGSRAH PLLRLKAAHA SLSNDSLNSG SASDGYCPRE HMLPCPLAAL ASRREDPRCG QPRPSRLDLD LPGCQAEPPA REATSADARV RTIKLSPTYQ HVPLLEGASR AGAEPLAGPG ISPGARKQAW LPADHLSKVP EKLAAAPLSV ASKALQKLAA QEGPLSLSRC SSLSSLSSAG RPGPSEGGDL DDSDSSLEGL EEAGPSEAEL DSTWRAPGAT SLPVAIPAPR RNRGRGLGVE DATPSSSSEN YVQETPLVLS RCSSVSSLGS FESPSIASSI PSEPCSGQGS GTISPSELPD SPGQTMPPSR SKTPPLAPAP QGPPEATQFS LQWESYVKRF LDIADCRERC RLPSELDAGS VRFTVEKPDE NFSCASSLSA LALHEHYVQQ DVELRLLPSA CPERGGGAGG AGLHFAGHRR REEGPAPTGS RPRGAADQEL ELLRECLGAA VPARLRKVAS ALVPGRRALP VPVYMLVPAP APAQEDDSCT DSAEGTPVNF SSAASLSDET LQGPPRDQPG GPAGRQRPTG RPTSARQAMG HRHKAGGAGR SAEQSRGAGK NRAGLELPLG RPPSAPADKD GSKPGRTRGD GALQSLCLTT PTEEAVYCFY GNDSDEEPPA AAPTPTHRRT SAIPRAFTRE RPQGRKEAPA PSKAAPAAPP PARTQPSLIA DETPPCYSLS SSASSLSEPE PSEPPAVHPR GREPAVTKDP GPGGGRDSSP SPRAAEELLQ RCISSALPRR RPPVSGLRRR KPRATRLDER PAEGSRERGE EAAGSDRASD LDSVEWRAIQ EGANSIVTWL HQAAAATREA SSESDSILSF VSGLSVGSTL QPPKHRKGRQ AEGEMGSARR PEKRGAASVK TSGSPRSPAG PEKPRGTQKT TPGVPAVLRG RTVIYVPSPA PRAQPKGTPG PRATPRKVAP PCLAQPAAPA KVPSPGQQRS RSLHRPAKTS ELATLSQPPR SATPPARLAK TPSSSSSQTS PASQPLPRKR PPVTQAAGAL PGPGASPVPK TPARTLLAKQ HKTQRSPVRI PFMQRPARRG PPPLARAVPE PGPRGRAGTE AGPGARGGRL GLVRVASALS SGSESSDRSG FRRQLTFIKE SPGLRRRRSE LSSAESAASA PQGASPRRGR PALPAVFLCS SRCEELRAAP RQGPAPARQR PPAARPSPGE RPARRTTSES PSRLPVRAPA ARPETVKRYA SLPHISVARR PDGAVPAAPA SADAARRSSD GEPRPLPRVA APGTTWRRIR DEDVPHILRS TLPATALPLR GSTPEDAPAG PPPRKTSDAV VQTEEVAAPK TNSSTSPSLE TREPPGAPAG GQLSLLGSDV DGPSLAKAPI SAPFVHEGLG VAVGGFPASR HGSPSRSARV PPFNYVPSPM VVAATTDSAA EKAPATASAT LLE //